The importance of claim construction, and how construing the same term facing a challenge based on different prior art in separate inter partes review proceedings can result in contrary.
The provisions of U.S. regulatory law regarding FDA approval for less than all the indications for which an innovator drug was approved under 21 U.S.C. § 355(j)(2)(A)(viii) (the.
The Hatch-Waxman Act allows a generic drugmaker to rely on a branded drugmaker’s Food and Drug Administration-approved New Drug Application if the generic drugmaker can show that the.
Late yesterday, the firm representing Federal Circuit Judge Pauline Newman in her district court case against Chief Judge Moore filed a brief asking the D.C. district court to deny the Council’s September Motion to Dismiss.
With summer in full swing, it's the perfect time to hang out in the pool and grill some burgers. Our case of the week involves an invention for doing both of those activities at the same time.